Small molecules targeting these mutated proteins have been shown to be effective in treating these cancers via inactivation of Ras/Raf/Mek/ERK signaling (Roberts and Der, 2007; Chapman et al., 2011; Barretina et al., 2012; Johnson and Puzanov, 2015). The gene discussed is MAP2K7; the disease is cancer.